RESEARCH ARTICLE

Methicillin-resistant Staphylococcus aureus (MRSA) nasal carriage among patients with diabetes at the Korle Bu Teaching Hospital

Ramzy B. Anafo¹, Yacoba Atiase², Fleischer C. N. Kotey¹,², Nicholas T. K. D. Dayie¹, Patience B. Tetteh-Quarcoo¹, Samuel Duodu¹, Mary-Magdalene Osei¹,², Khalid J. Alzahrani⁵, Eric S. Donkor¹*

¹ Department of Medical Microbiology, University of Ghana Medical School, Korle Bu, Accra, Ghana, ² Department of Medicine, University of Ghana Medical School, Korle Bu, Accra, Ghana, ³ FleRhoLife Research Consult, Teshie, Accra, Ghana, ⁴ Department of Biochemistry, Cell and Molecular Biology and West African Centre for Cell Biology of Infectious Pathogens, University of Ghana, Legon, Accra, Ghana, ⁵ Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia

* esampane-donkor@ug.edu.gh, ericsdon@hotmail.com

Abstract

Aim
To investigate the epidemiology of S. aureus and MRSA nasal carriage among people with diabetes at the Korle Bu Teaching Hospital in Accra, including the prevalence, predictors of carriage, and antibiotic resistance.

Methodology
This study was cross-sectional, involving 300 diabetes patients and 106 non-diabetic individuals. Swab specimens of the nares were obtained from the participants and bacteriologically cultured. Identification and characterization of S. aureus and MRSA were based on standard bacteriological methods; antimicrobial susceptibility testing was by the Kirby-Bauer method.

Results
The prevalence of staphylococcal carriage, the diabetes group relative to the non-diabetes group, were 31.0% and 10.4% (S. aureus), and 3.3% and 0.0% (MRSA). Presence of diabetes predisposed to S. aureus carriage, but not MRSA nor coagulase-negative staphylococci (CoNS) carriage ($OR = 3.88; p < 0.0001$). Colonization with CoNS was protective of S. aureus ($OR = 0.039, p < 0.001$) and MRSA ($OR = 0.115, p = 0.043$) colonization among the diabetics. The antimicrobial resistance patterns recorded among the S. aureus isolated from the diabetic individuals relative to the non-diabetics were as follows: penicillin (95% vs. 91%), tetracycline (37% vs. 27%), cotrimoxazole (30% vs. 36%), erythromycin (17% vs. 0%), norfloxacin (13% vs. 0%), clindamycin (12% vs. 0%), gentamicin (9% vs. 0%), fusidic acid (10% vs. 9%), linezolid (4% vs. 0%), and rifampicin (5% vs. 0%). The proportion of
multidrug resistant *S. aureus* was 41% (*n* = 38) in the diabetes group and 0% in the non-diabetes group; this difference was statistically significant (*p* = 0.01).

**Conclusions**

The presence of diabetes predisposed the participants to *S. aureus* carriage by almost four folds, but not MRSA carriage. Colonization with CoNS was protective of *S. aureus* and MRSA carriage in the diabetes group. Finally, linezolid remains a good therapeutic agent for anti-MRSA therapy.

**Introduction**

*Staphylococcus aureus* (*S. aureus*) is concurrently a commensal and a human pathogen [1,2]. Its pathogenic nature is seen in its implication in infections such as meningitis, septicaemia, pneumonia, endocarditis and osteomyelitis [2]. A key predisposing factor to these infections is carriage of the pathogen on the human body, which could occur on the skin, perineum, pharynx, gastrointestinal tract, vagina, or the axillae, but more frequently in the anterior nares, and thus making the anterior nares the predominant antecedent to invasive *S. aureus* infections [2–4]. Consequently, two broad categories of *S. aureus* carrier states have been identified—persistent carriage, which occurs in about a fifth of the general population, and intermittent carriage which occurs in about a third [5–7]. Non-carriers, who comprise about half of the general population, have been presumed to be resistant to *S. aureus* carriage [5–8].

Based on their susceptibility to methicillin, *S. aureus* strains have been identified as methicillin-resistant *S. aureus* (MRSA) and methicillin-susceptible *S. aureus* (MSSA). The methicillin resistance trait simultaneously confers on the organisms resistance to all beta-lactam antibiotics [9–11]. Like most other pathogens, *S. aureus* has additionally been classified into healthcare-associated, community-associated, and livestock-associated, based on the origin of infection; consequently, MRSA strains have also been categorized as healthcare-associated MRSA (HA-MRSA) [12], community-associated MRSA (CA-MRSA) [13–16], and livestock-associated MRSA (LA-MRSA) [17,18].

Factors that predispose to *S. aureus* carriage have been extensively studied, and have been noted to include non-ambulatory status, previous hospitalization, chronic haemodialysis, previous antibacterial therapy, previous MRSA infection or colonization, previous ICU admission, HIV infection, and diabetes mellitus [19–23]. Several studies have shown that many of the clinical infections with *S. aureus* arise by virtue of spread from healthy carriers, thus demonstrating that carrying out studies on predictors of *S. aureus* carriage is integral to understanding the potential for MRSA transmission and invasive infections [24,25]. MRSA poses an important public health threat as it is refractory to major antibiotic groups in routine use [26–28] and is a consistent etiology of outbreaks [29–31]. Besides, its infections are synchronous with extended hospital stays coupled with increased healthcare costs which could be as high as 44 million Euros [30–32].

Individuals with diabetes, 79% of whom are in low- and middle-income countries [33], have an increased risk of *S. aureus* and MRSA carriage [34–37]. Nasal carriage of *S. aureus* has been identified in several studies as an important pre-requisite for its infections [3,38]. Thus people with diabetes comprise an important risk group for *S. aureus* and MRSA carriage and infections. Yet, the determinants of *S. aureus* and MRSA carriage in this risk population have not been well studied. Most MRSA carriage studies appear to have focused on the general...
population [39,40] and a few risk groups, such as HIV-infected persons [41–43] and sickle cell disease patients [44]. In Africa, the prevalence of *S. aureus* and MRSA carriage among diabetic individuals, antibiogram of colonizing strains, as well as predictors of carriage of the pathogen are largely unknown. Such information would contribute to tailored prevention and control measures in this risk group and help reduce the morbidity and mortality associated with diabetes. Hence this study investigated the epidemiology of *S. aureus* and MRSA nasal carriage among diabetes patients at the Korle Bu Teaching Hospital (KBTH), including the relationship between diabetes and carriage of *S. aureus* and MRSA, predictors of carriage, and *S. aureus* antimicrobial resistance patterns.

**Materials and methods**

**Study site, design, and sampling**

This study was approved by the Ethical and Protocol Review Committee of the College of Health Sciences, University of Ghana (Unique identifier: “CHS-Et/M.3–9.16/2019-2020”), and the Institutional Review Board of KBTH (Unique identifier: “KBTH-STC/IRB/000144/2019”). Written informed consent was also obtained from all the participants. The study was carried out at the National Diabetes Management and Research Centre (NDMRC) and the Department of Surgery (specifically, the Ulcer Clinic), which are both located on the premises of the Korle Bu Teaching Hospital (KBTH). The NDMRC is a national resource centre for diabetes care, training, and research, offering mainly outpatient services. It is the largest diabetes centre in Ghana, and receives patients from hospitals and clinics around the country, as well as clinics and wards within the hospital. It has over 5000 registered patients and an average daily outpatient attendance of about 70–80 persons. Management of DFU at the NDMRC is often dependent on the patient and the ulcer; of interest is the location and stage of the ulcer, glycaemic control, the presence or otherwise of peripheral artery disease, and neuropathy. For plantar ulcers, offloading is encouraged; however the absence of offloading devices makes most patients non-adherent. With regard to the daily wound dressing, it is done with saline for clean wounds. As regards infected wounds, the cleaning is done with iodinated povidone and metronidazole solution; papain-urea ointment is applied when there is slough. Systemic antibiotics are also prescribed for infected wounds. There is additionally serial surgical debridement on outpatient basis or admission for debridement in the theatre when needed–when peripheral artery disease is present, vascular surgeons are involved, but the cost of these procedures are often prohibitive for most patients. All these are done in addition to optimization of glucose control.

The study had a cross-sectional design, and involved sampling 300 diabetes patients and 106 non-diabetic individuals (serving as the control group) during the period January to June 2020. Recruitment of the diabetes patients was based on the following inclusion criteria: being a diabetes patient, and aged between 13 and 80 years. The non-diabetics were recruited based on their fasting/random blood sugar levels. Individuals with fasting blood sugar levels less than or equal to 7.0 mmol/l and less than or equal to 11.1 mmol/l for random blood sugar results (and not on glucose-lowering medications) were considered eligible for the study. The exclusion criteria for both the study and control groups were: refusal to participate, presence of severe disease (disease warranting hospitalization), and history of recent (two weeks) antimicrobial therapy.

After obtaining informed consent, information on possible predictors of colonization with *S. aureus* and MRSA (such as a history of pneumonia or tuberculosis [TB], owing to the association of the conditions with the respiratory tract) were gathered from the participants using a standard questionnaire, as well as anterior nasal swabs by a qualified physician, via rotation of
sterile cotton swabs five times at the anatomical site. Each specimen was subsequently kept in an already-labeled 1 ml skim milk-tryptone-glucose-glycerin (STGG)-contained vial, and within four hours of collection, conveyed to the Department of Medical Microbiology, University of Ghana Medical School, for laboratory processing. The processing involved an initial two-minute vortexing and a subsequent storage at -80 °C, until needed.

**Laboratory analysis**

Specimen processing, *S. aureus* and MRSA identification, antimicrobial susceptibility testing, and molecular investigations were done as previously described [43], with a few modifications. Media used in the culture of the specimens were blood, chocolate, MacConkey, and Mannitol salt agars. For each sample, all staphyloccocal colonies with different morphologies were selected for follow-ups. Presumptive staphyloccal identification was with the aid of colonial morphology and reaction to Gram stain. Staphyloccocal isolates that were coagulase-negative and -positive were respectively identified as coagulase-negative staphyloccoci (CoNS) and *S. aureus*. The latter were tested against penicillin (10 μg), tetracycline (30 μg), cefoxitin (30 μg), cotrimoxazole (1.25 μg trimethoprim + 23.75 μg sulphamethoxazole), erythromycin (15 μg), norfloxacin (10 μg), clindamycin (2 μg), gentamicin (10 μg), fusidic acid (10 μg), linezolid (10 μg), and rifampicin (5 μg), to determine their susceptibility, in accordance with Clinical and Laboratory Standards Institute (2020) guidelines. *S. aureus* ATCC 25923 was used as the control strain. Cefoxitin-resistant *S. aureus* were confirmed as *S. aureus* by means of polymerase chain reaction (PCR) amplification of the *nucA* gene, and as MRSA through PCR amplification of the *meca* gene.

During the molecular analyses, genomic DNA were extracted with the Zymo Research extraction kit (Zymo Research Corp., Irvine, USA) (as directed by the manufacturer) from an overnight lysogenic broth culture of each MRSA isolate, as well as that of an MRSA positive control strain. For each isolate, a mixture of extracted DNA (5 μL volume) and bromophenol blue gel loading buffer (2 μL volume) was separated using a 1.2% agarose gel electrophoresis, followed by UV-aided visualization of resultant bands (as a quality control measure). Subsequently, each extracted DNA served as a template for the *meca* and *nucA* PCRs.

**Data analysis**

The software STATA 14 (Strata Corp, College Station, TX, USA) was used for the data analysis. Besides using descriptive statistics to summarize demographic, clinical, and antimicrobial resistance data, univariate and multivariate analyses (including odds ratios and 95% confidence intervals, at a 0.05 alpha level) were used to identify predictors of colonization with *S. aureus* and MRSA.

**Ethical approval**

This study was approved by the Ethical and Protocol Review Committee of the College of Health Sciences, University of Ghana (Unique identifier: "CHS-Et/M.3–9.16/2019-2020"), and the Institutional Review Board of KBTH (Unique identifier: "KBTH-STC/IRB/000144/2019").

**Results**

**Sociodemographic and clinical features of the participants**

In total, four hundred and six (406) individuals—two hundred (200) diabetic individuals without foot ulcers, one hundred (100) diabetic individuals with foot ulcers, and one-hundred and six (106) non-diabetic individuals—participated in the study. Their sociodemographic data are
presented in Table 1. Females were the majority in both groups, representing 74.7% (n = 224) and 50.9% (n = 54) among the diabetics and non-diabetics respectively. With regard to age, majority of the participants in the diabetes group were older than 60 years of age (53.7%, n = 161), whereas in the non-diabetes group, the 30–60 year old group had the most participants. The major type of residence inhabited by the participants of the diabetes group was self-contained apartments (54.0%, n = 162), whereas that of the non-diabetes group was compound houses (51.9%, n = 55). Furthermore, the participants in both study groups reported washing their hands with soap often [diabetes group (80.3%, n = 241); non-diabetes group (92.5%, n = 98)].

As regards the participants’ clinical features, none of the participants in the non-diabetes group had an history of hospitalization in the past year, history of pneumonia, or presence of foot ulcers, while 0.5% (n = 1) and 4.2% (n = 8) respectively had a history of tuberculosis and surgery. In the diabetes group, majority of the participants lacked a history of hospitalization in the past year (61.7%, n = 185), presence of foot ulcer (66.7%, n = 200), history of pneumonia (97.3%, n = 292), tuberculosis (98.7%, n = 296), and a history of surgery (58.7%, n = 176). Details of the clinical features are presented in Table 2.

### Relationship between diabetes and staphylococcal carriage

The prevalence of staphylococcal carriage, the diabetes group relative to the non-diabetes group, were 31.0% and 10.4% (*S. aureus*), and 3.3% and 0.0% (MRSA) (Table 3). Presence of diabetes was not significantly associated with MRSA carriage, but significantly associated with *S. aureus* carriage.

### Table 1. Demographic and household characteristics of the study participants.

| Demographic and household characteristics | Diabetics     | Non-Diabetics |
|-------------------------------------------|---------------|---------------|
| Number %                                  | Number %      |
| **Age (in years)**                        |               |
| 14–19                                      | 1             | 4             |
| 20–29                                      | 2             | 29            |
| 30–60                                      | 136           | 69            |
| >60                                        | 161           | 4             |
| **Gender**                                |               |
| Male                                       | 76            | 52            |
| Female                                     | 224           | 54            |
| **Type of residence**                     |               |
| Self-contained                             | 162           | 51            |
| Compound                                   | 138           | 55            |
| **Number of individuals in household**     |               |
| <5                                         | 108           | 51            |
| 5–10 persons                               | 179           | 51            |
| 11–20 persons                              | 13            | 4             |
| **Presence of health worker in household** |               |
| Yes                                        | 74            | 53            |
| No                                         | 225           | 53            |
| **Hand washing with soap**                 |               |
| Rarely                                     | 59            | 8             |
| Often                                      | 241           | 98            |

Age (Diabetics) (\(\bar{X}, SD\)) = 60.73, 13.28 years; Age (Non-Diabetics) (\(\bar{X}, SD\)) = 37.26, 12.22 years; Number of individuals in household (Diabetics) (\(\bar{X}, SD\)) = 5.81, 2.75 persons; Number of individuals in household (Non-Diabetics) (\(\bar{X}, SD\)) = 5.14, 2.59 persons.

https://doi.org/10.1371/journal.pone.0257004.t001
(OR = 3.88, p < 0.0001), with diabetes conferring an almost four-fold risk of *S. aureus* carriage. Eight of the *S. aureus* nasal carriers had concurrent *S. aureus* presence in their foot ulcers.

**Predictors of *S. aureus* and MRSA colonization among the diabetics and non-diabetics**

Among the diabetics, colonization with coagulase-negative *Staphylococci* was protective of *S. aureus* (OR = 0.039, p < 0.001, 95% CI = 0.02–0.08) and MRSA colonization (OR = 0.115, p = 0.043, 95% CI = 0.014–0.932). However, no predictors of *S. aureus* and MRSA colonization were identified among the non-diabetics.

**Antimicrobial resistance patterns of the *S. aureus* isolates**

The highest proportion of *S. aureus* resistance to the various antimicrobials was recorded for penicillin (95% in the diabetes group and 91% in the non-diabetes group). Also, no resistance was recorded against any of linezolid, rifampicin, gentamicin, clindamycin, norfloxacin, and

---

**Table 2. Clinical features of the study participants.**

| Clinical features                        | Diabetics |      | Non-Diabetics |      |
|-----------------------------------------|-----------|------|---------------|------|
|                                         | Number    | %    | Number        | %    |
| **Self-reported self-medication**       |           |      |               |      |
| Yes                                     | 109       | 36.3 | 39            | 20.6 |
| No                                      | 191       | 63.7 | 67            | 35.4 |
| **History of hospitalization in the past year** |           |      |               |      |
| Yes                                     | 115       | 38.3 | 0             | 0    |
| No                                      | 185       | 61.7 | 106           | 100.0|
| **Presence of foot ulcer**              |           |      |               |      |
| Yes                                     | 100       | 33.3 | 0             | 0    |
| No                                      | 200       | 66.7 | 106           | 100  |
| **History of pneumonia in the past year** |           |      |               |      |
| Yes                                     | 8         | 2.7  | 0             | 0    |
| No                                      | 292       | 97.3 | 106           | 100  |
| **History of tuberculosis in the past year** |           |      |               |      |
| Yes                                     | 4         | 1.3  | 1             | 0.5  |
| No                                      | 296       | 98.7 | 105           | 99.5 |
| **History of surgery in the past year** |           |      |               |      |
| Yes                                     | 124       | 41.3 | 8             | 4.2  |
| No                                      | 176       | 58.7 | 98            | 51.9 |

Number of hospitalizations (Diabetics) (X, SD) = 0.61, 0.97; Number of hospitalizations (Non-Diabetics) (X, SD) = 0.00, 0.00;

* Refers to participants’ reported self-medication with antibiotics and other medications within the past year.

**Table 3. A comparison of the study participants on their staphylococcal carriage.**

| Staphylococci | Diabetics | Non-Diabetics | OR (95% CI) | p value |
|---------------|-----------|---------------|-------------|---------|
|               | Prevalence (%) | Prevalence (%) |             |         |
| *S. aureus*   | 31.0% (*n* = 93) | 10.4% (*n* = 11) | 3.88* (3.89–7.59) | <0.0001 |
| MRSA          | 3.3% (*n* = 10) | *(n* = 0) | – | – |
| CoNS          | 57.0% (*n* = 171) | 46.2% (*n* = 49) | 1.54 (0.99–2.41) | 0.06 |

*Significant at 0.05 alpha level.

https://doi.org/10.1371/journal.pone.0257004.t003
erythromycin in the non-diabetes group. In the diabetes group, the resistance rates recorded against each of these six antibiotics ranged between 4% and 17%. The resistance rates recorded against cotrimoxazole were 30% in the diabetes group and 36% in the non-diabetes group. None of these differences in antibiotic resistance rates was statistically significant. However, as regards the proportion of multidrug resistance (MDR) (resistance to three or more antimicrobial classes, penicillin inclusive) among the *S. aureus* isolates, the diabetes group recorded 41% \((n = 38)\), whereas the non-diabetes group recorded 0% \((n = 0)\), and this difference was statistically significant \((p = 0.01)\); even when penicillin was excluded from the determination of MDR, the MDR rate remained higher in the diabetes group \((21\%; n = 20)\) than in the control group \((0\%; n = 0)\), albeit not statistically significant \((p = 0.09)\). Moreover, a comparison of the antibiotic resistance rates between the MRSA and MSSA isolates of the diabetes group demonstrated statistically significant differences for tetracycline \((\text{MRSA} = 70\% [7/10]; \text{MSSA} = 33\% [27/83]; p = 0.02)\), norfloxacin \((\text{MRSA} = 4\% [4/10]; \text{MSSA} = 10\% [8/83]; p = 0.01)\), and gentamicin \((\text{MRSA} = 30\% [3/10]; \text{MSSA} = 6\% [5/83]; p = 0.01)\), but not penicillin \((\text{MRSA} = 0\% [0/10]; \text{MSSA} = 94\% [78/83]; p = 0.42)\), erythromycin \((\text{MRSA} = 0\% [0/10]; \text{MSSA} = 19\% [16/83]; p = 0.13)\), clindamycin \((\text{MRSA} = 0\% [0/10]; \text{MSSA} = 13\% [11/83]; p = 0.22)\), linezolid \((\text{MRSA} = 0\% [0/10]; \text{MSSA} = 5\% [4/83]; p = 0.48)\), cotrimoxazole \((\text{MRSA} = 40\% [4/10]; \text{MSSA} = 29\% [24/83]; p = 0.47)\), rifampicin \((\text{MRSA} = 0\% [0/10]; \text{MSSA} = 6.0\% [5/83]; p = 0.42)\), norfusidic acid \((\text{MRSA} = 10\% [1/10]; \text{MSSA} = 10\% [8/83]; p = 0.97)\). A comparison of the rates of antimicrobial resistance of *S. aureus* between the diabetes and non-diabetes groups is presented in Fig 1.

**Discussion**

This study appears to be the first to investigate the epidemiology of *S. aureus* and MRSA carriage among diabetics in Ghana, as well as one of the few MRSA carriage studies conducted among populations with diabetes in Africa and other parts of the world.

Individuals with diabetes had a higher odds for carriage of *S. aureus* \((31.0\% \text{ vs. } 10.4\%)\), but not MRSA \((3.3\% \text{ vs. } 0.0\%)\). It is important to note that this is not the first time that a risk population has been associated with a higher odds for *S. aureus* carriage, but not MRSA carriage. Donkor *et al.* [43] and Appiah *et al.* [44] made a similar observation among HIV-infected and sickle cell disease patients respectively in their studies conducted within the same geographical area as this study. This observation may be due to the low MRSA prevalence recorded by these

![Fig 1.](https://doi.org/10.1371/journal.pone.0257004.g001)
studies (< 4%), as was also the occurrence in the current study, probably stemming from the generally-low MRSA prevalence in the country [45].

The S. aureus nasal carriage prevalence recorded in the current study falls within the nasal carriage prevalence of 8%–44.9% reported among other risk groups in the country [41,43,44]. It is also comparable to the 32.8% prevalence reported among a diabetic population in Egypt [46], and seems higher than that reported by Lin et al. [47] (8.7%) and Lin et al. [48] (16.4%) among two diabetic populations in China, but higher than those reported by Kutlu et al. [49], Ahluwalia et al. [50], and Saxena et al. [51] respectively among diabetic populations in Turkey (41.8%), Australia (56.7%) and Saudi Arabia (72.4%). It needs to be pointed out, though, that the diabetic population sampled in the study of Ahluwalia et al. [50] were on hospital admission, and that of Saxena et al. [51] additionally had end-stage renal disease, and were receiving haemodialysis. These may account for their apparently higher S. aureus prevalence. The MRSA prevalence recorded in the current study however fell within the range of 0–8.5% reported in these studies [46–51].

Colonization with coagulase-negative Staphylococci was protective of S. aureus and MRSA colonization among the diabetics. This means absence of colonization with CoNS increased the odds of S. aureus and MRSA colonization. This is consistent with the reported inverse relationship between S. aureus and CoNS, which has been attributed to production of the S. aureus-cidal autoinducing peptide by CoNS [52–54].

The highest proportion of S. aureus resistance to the various antimicrobials was recorded for penicillin (95% in the diabetes group and 91% in the non-diabetes group). Owing to the wide usage of the antibiotic, previous studies in the country have also reported similar penicillin resistance rates among S. aureus [40,41,43,44]. These studies additionally recorded similar antimicrobial resistance rates for the other antimicrobials investigated [40,41,43,44]. Given the high resistance displayed against cotrimoxazole in the current study, it may be imperative to re-examine its usefulness as an antibiotic prophylaxis. Linezolid recorded low resistance rates, suggesting that it is still useful as an anti-MRSA agent. However, as it is one of the limited mainstays of anti-MRSA therapy, the 4% resistance rate recorded against the antimicrobial in the diabetes group underscores the need to step up campaigns against indiscriminate antimicrobial use. This recommendation is reinforced by the 40% MDR proportion recorded in the diabetes group.

Interpretation of the findings of this study is limited by absence of data on glycaemic control and grade and duration of DFU among the diabetics, as well as the relatively smaller number of non-diabetics. Besides, given the age-prevalent nature of diabetes, the majority of the participants in the diabetes group were older than 60 years of age, whereas in the non-diabetes group, the 30–60 year old group had the most participants. Also, the study lacks data on participants’ previous antimicrobial therapy in the context of agents, route of administration, and duration of therapy. Moreover, concordance of S. aureus carriage and foot ulcer infection could not be determined for the eight concomitant S. aureus carriers given the absence of genotypic data.

**Conclusion**

The presence of diabetes predisposed the participants to S. aureus carriage by almost four folds, but not MRSA carriage. Moreover, colonization with CoNS was protective of S. aureus and MRSA carriage in the diabetes group. Finally, linezolid remains a good therapeutic agent for anti-MRSA therapy.

In light of the high proportion of multidrug resistant S. aureus in the diabetes group, it is necessary to continue carrying out MRSA surveillance studies among diabetic individuals and other risk groups for S. aureus and MRSA carriage.
Supporting information

S1 File. (DOCX)

Acknowledgments

The authors acknowledge the following individuals for their contributions: the study participants, staff of the National Diabetes Management and Research Centre (NDMRC) and the Department of Surgery, Korle Bu Teaching Hospital, and technical staff of the Departments of Medical Microbiology, University of Ghana Medical School, and the Department of Biochemistry, Cell and Molecular Biology/West African Centre for Cell Biology of Infectious Pathogens.

Author Contributions

**Conceptualization:** Eric S. Donkor.

**Data curation:** Ramzy B. Anafo, Fleischer C. N. Kotey, Patience B. Tetteh-Quarcoo, Eric S. Donkor.

**Formal analysis:** Ramzy B. Anafo, Yacoba Atiase, Fleischer C. N. Kotey, Patience B. Tetteh-Quarcoo, Samuel Duodu, Khalid J. Alzahrani, Eric S. Donkor.

**Investigation:** Ramzy B. Anafo, Yacoba Atiase, Fleischer C. N. Kotey, Nicholas T. K. D. Dayie, Patience B. Tetteh-Quarcoo, Samuel Duodu, Mary-Magdalene Osei, Eric S. Donkor.

**Methodology:** Ramzy B. Anafo, Yacoba Atiase, Fleischer C. N. Kotey, Nicholas T. K. D. Dayie, Patience B. Tetteh-Quarcoo, Samuel Duodu, Eric S. Donkor.

**Project administration:** Ramzy B. Anafo, Fleischer C. N. Kotey, Nicholas T. K. D. Dayie, Mary-Magdalene Osei, Eric S. Donkor.

**Resources:** Ramzy B. Anafo, Yacoba Atiase, Fleischer C. N. Kotey, Nicholas T. K. D. Dayie, Patience B. Tetteh-Quarcoo, Samuel Duodu, Mary-Magdalene Osei, Khalid J. Alzahrani, Eric S. Donkor.

**Software:** Ramzy B. Anafo, Yacoba Atiase, Fleischer C. N. Kotey, Nicholas T. K. D. Dayie, Patience B. Tetteh-Quarcoo, Samuel Duodu, Mary-Magdalene Osei, Khalid J. Alzahrani, Eric S. Donkor.

**Supervision:** Yacoba Atiase, Fleischer C. N. Kotey, Nicholas T. K. D. Dayie, Eric S. Donkor.

**Validation:** Yacoba Atiase, Fleischer C. N. Kotey, Nicholas T. K. D. Dayie, Patience B. Tetteh-Quarcoo, Samuel Duodu, Mary-Magdalene Osei, Khalid J. Alzahrani, Eric S. Donkor.

**Visualization:** Ramzy B. Anafo, Yacoba Atiase, Fleischer C. N. Kotey, Patience B. Tetteh-Quarcoo, Samuel Duodu, Mary-Magdalene Osei, Khalid J. Alzahrani, Eric S. Donkor.

**Writing – original draft:** Fleischer C. N. Kotey, Eric S. Donkor.

**Writing – review & editing:** Ramzy B. Anafo, Yacoba Atiase, Fleischer C. N. Kotey, Nicholas T. K. D. Dayie, Patience B. Tetteh-Quarcoo, Samuel Duodu, Mary-Magdalene Osei, Khalid J. Alzahrani, Eric S. Donkor.

References

1. Williams REO (1963). Healthy carriage of Staphylococcus aureus: its prevalence and importance. *Bacteriology Reviews*, 27 (1), 56–71. [https://doi.org/10.1128/bbr.27.1.56-71.1963](https://doi.org/10.1128/bbr.27.1.56-71.1963) PMID: 1400926
2. Obeng-Nkromah N, Labi AK, Acquah ME, Donkor ES (2015). Bloodstream infections in patients with malignancies: implications for antibiotic treatment in a Ghanaian tertiary setting. BMC Res Notes, 8:742. https://doi.org/10.1186/s13104-015-1701-z PMID: 26628056

3. Von Elff C, Becker K, Machka K, Stammer H, & Peters G (2001). Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med, 344:11–6. https://doi.org/10.1056/NEJM20010104344102 PMID: 11136954

4. Foster TJ (2005). Immune evasion by staphylococci. Nature Reviews Microbiology, 3 (December), 948–958. https://doi.org/10.1038/nrmicro1289 PMID: 16322743

5. Hu L, Umeda A, Kongo S, & Amako K (1995). Typing of Staphylococcus aureus colonising human nasal carriers by pulsed-field gel electrophoresis. Journal of Medical Microbiology, 42 (2), 127–32. https://doi.org/10.1099/00222615-42-2-127 PMID: 7869348

6. Kluytmans JAN & Verbrugh H (1997). Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated Risks. Clinical Microbiology Reviews, 10 (3), 505–520. https://doi.org/10.1128/CMR.10.3.505 PMID: 9227864

7. Nouwen J, Boelens H, van Belkum A, & Verbrugh H (2004). Human factor in Staphylococcus aureus nasal carriage. Infection and Immunity, 72 (11), 6685–6688. https://doi.org/10.1128/IAI.72.11.6685-6688.2004 PMID: 15501803

8. Eriksen NH, Espersen F, Rosdahl VT, & Jensen K (1995). Carriage of Staphylococcus aureus among 104 healthy persons during a 19-month period. Epidemiology and Infection, 115 (1), 51–60. https://doi.org/10.1017/s0950268800058118 PMID: 7641838

9. File TM Jr., Wilcox MH, & Stein GE (2012). Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clinical Infectious Diseases, 55, (Suppl 3), S173–S180. https://doi.org/10.1093/cid/cis559 PMID: 22903949

10. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M & Lewis JS (2012). Methicillin-resistant Staphylococcus aureus bacteremia and endocarditis treated with ceftaroline salvage therapy. Journal of Antimicrobial Chemotherapy, 67 (5), 1287–1270. https://doi.org/10.1093/jac/dks006 PMID: 22311935

11. Polenakovik HM & Pleiman CM (2013). Ceftaroline for methicillin-resistant Staphylococcus aureus bacteremia: case series and review of the literature. International Journal of Antimicrobial Agents, 42 (5), 450–455. https://doi.org/10.1016/j.ijantimicag.2013.07.005 PMID: 23993067

12. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. (2006). Methicillin-resistant Staphylococcus aureus infections among patients in the emergency department. The New England Journal of Medicine, 355 (7), 668–674. https://doi.org/10.1056/NEJMoa053536 PMID: 16914702

13. Camargo CH, da Cunha MDEL, Bonesso MF, da Cunha FP, Barbosa AN, & Fortaleza CM (2013). Systemic CA-MRSA infection following trauma during soccer match in inner Brazil: clinical and molecular characterization. Diagnostic Microbiology and Infectious Disease, 76 (3), 372–374. https://doi.org/10.1016/j.diagmicrobio.2013.03.013 PMID: 23602786

14. Casey JA, Cosgrove SE, Stewart WF, Pollak J & Schwartz BS (2013). A population-based study of the epidemiology and clinical features of methicillin-resistant Staphylococcus aureus infection in Pennsylvania, 2001–2010. Epidemiology and Infection, 141 (6), 1166–1179. https://doi.org/10.1017/S0950268811000433 PMID: 22929058

15. Joore IKCW, Rooijen MS, Van MFS, Loeffler D, Neeling AJ, De Dam A. et al. (2013). First report in South America of companion animal colonization by the USA1100 clone of community-acquired methicillin-resistant Staphylococcus aureus (ST30) and by the European clone of methicillin-resistant Staphylococcus pseudintermedius (ST71). BMC Research Notes, 6, 336. https://doi.org/10.1093/bcrn/bct250 PMID: 23468471

16. Loeffler A, Mccarthy A, Lloyd DH, Musilová E, Pfeiffer DJ & Lindsay JA (2013). Whole-genome comparison of meticillin-resistant Staphylococcus aureus CC22 SCCmec IV from people and their in-contact pets. Veterinary Dermatology, 24 (5), 538–e128. https://doi.org/10.1111/vde.12062 PMID: 23869430

17. Haenni M, Saras E, Châtre P, Médaille C, Bes M, Madec JY, et al. (2012). A USA300 variant and other human-related meticillin-resistant Staphylococcus aureus strains infecting cats and dogs in France. Journal of Antimicrobial Chemotherapy, 67, 326–329. https://doi.org/10.1093/jac/dkr499 PMID: 22146878

18. Quítoco IM, Raimundo MS, Silva-Carvalho MC, Souza RR, Beltrame CO, de Oliveira TF, et al. (2013). Rötter H, Hinkelmann K (2001). A study of the impact of meticillin-resistant Staphylococcus aureus bacteremia among 104 healthy persons during a 19-month period. Epidemiology and Infection, 115 (1), 51–60. https://doi.org/10.1017/s0950268800058118 PMID: 7641838

19. Tacconelli E, Venkataraman L, De Girolami PC, & D’Agata EM (2004). Methicillin-resistant Staphylococcus aureus bacteremia diagnosed at hospital admission: distinguishing between community-acquired versus healthcare-associated strains. Journal of Antimicrobial Chemotherapy, 53, 474e479. https://doi.org/10.1093/jac/dkh107 PMID: 14762054

MRSA nasal carriage among patients with diabetes
20. Cenizal MJ, Hardy RD, Anderson M, Katz K, & Skiest DJ (2008). Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization in HIV-infected ambulatory patients. J Acquir Immune Defic Syndr, 48(5), 567–571. https://doi.org/10.1097/QAI.0b013e31817e9679 PMID: 18645516

21. Kyaw WM, Lee WK, Shiong WC, Chow A, Ping ACL, Ang B, et al (2012). Prevalence of and risk factors for MRSA colonization in HIV-positive outpatients in Singapore. AIDS Research and Therapy, 9(33), 1–6.

22. Farley JE, Hayat MJ, Mph PLS, BS TR, Ascp MT, & Carroll K (2015). Prevalence and risk factors for methicillin-resistant Staphylococcus aureus in an HIV-positive cohort. American Journal of Infection Control, 43(4), 329–335. https://doi.org/10.1016/j.ajic.2014.12.024 PMID: 25683758

23. Kotpal RSKP, Bhalia P, Dewan R, & Kaur R (2015). Incidence and risk factors of nasal carriage of Staphylococcus aureus in HIV-infected individuals in comparison to HIV-uninfected individuals: a case-control study. Journal of the International Association of Providers of AIDS Care, 1–7. https://doi.org/10.1177/232997414554005.

24. Peacock SJ & Paterson GK (2015). Mechanisms of methicillin resistance in Staphylococcus aureus. Annual Review of Biochemistry, 84, 1–28. https://doi.org/10.1146/annurev-biochem-060614-034516 PMID: 26034887

25. Bogaert D, van Belkum A, Sluijter M, Luijendijk A, de Groot R, Rümptke HC, et al. (2004). Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. The Lancet; 363(9424), P1871–P1872. https://doi.org/10.1016/S0140-6736(04)16357-5 PMID: 15183627

26. Chambers HF (1997). Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clinical Microbiology Reviews, 10, 781–791. https://doi.org/10.1128/CMR.10.4.781 PMID: 936672

27. Han LL, McDougal LK, Gorwitz RJ, Mayer KH, Patel JB, Sennott JM, et al. (2007). High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. Journal of Clinical Microbiology, 45(4), 1350–1352. https://doi.org/10.1128/JCM.02274-06 PMID: 17287335

28. Chambers HF & Deleo FR (2009). Waves of resistance: Staphylococcus aureus in the antibiotic era. Nature Reviews Microbiology, 7, 629–641. https://doi.org/10.1038/nrmicro2022 PMID: 19680247

29. Hall GS (2003). MRSA: Lab detection, epidemiology, and infection control. Microbiology Frontline, 3, 1–6.

30. Kleven RS, Edwards JR, Richards CL Jr, Horan TC, Gaynes RP, Pollock DA, et al. (2007). Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Reports, 122(2), 160–166. https://doi.org/10.1177/003335490712200205 PMID: 17357358

31. De Kraker ME, Wolkezitz M, Davey PG, Koller W, Berger J, Nagler J, et al. (2011). Clinical impact of Staphylococcus aureus in type 2 diabetic patients from communities. JPract Med, 31, 4133–4135. https://doi.org/10.1016/j.jpracmed.2011.05.005 PMID: 21229533

32. Eltchauser A & Steiner C (2007). Infections with methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrobial Agents & Chemotherapy, 55(4), 1598–1605. https://doi.org/10.1128/AAC.01157-10 PMID: 21229533

33. International Diabetes Federation. (2019). IDF Diabetes Atlas, 9th edn. Brussels, Belgium. https://www.diabetesatlas.org.

34. Chen CC, & Pass SE (2013). Risk factors for and impact of methicillin-resistant Staphylococcus aureus nasal colonization in patients with diabetes at a medical intensive care unit. Am J Infect Control, 41, 1100–1101. https://doi.org/10.1016/j.ajic.2013.01.035 PMID: 23663856

35. Hart J, Hamilton EJ, Makepeace A, et al. (2015). Prevalence, risk factors and sequelae of Staphylococcus aureus carriage in diabetes: The Fremantle Diabetes Study Phase II. JDiabetes Complications, 29, 1092–1097. https://doi.org/10.1016/j.jdiacomp.2015.06.005 PMID: 26243688

36. Huifen Y, Junshao Z, Wenzhou Q, et al. (2015). Study on colonization status and risk factors of methicillin-resistant Staphylococcus aureus in patients of intense care units. Chin J Dis Infect, 32: 4–26.

37. Yan L, Ping X, Lin D, et al. (2015). Nasal colonization prevalence and risk factors of methicillin-resistant Staphylococcus aureus in type 2 diabetic patients from communities. J Pract Med, 31, 4133–4135.

38. Wertheim HFL, Melles DC, Vos MC, Leeuwen W, Van Belkum A, Van Verbrugh H A, et al. (2005). The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Disease, 5(December), 751–762. https://doi.org/10.1016/S1473-3099(05)70295-4 PMID: 16310147

39. Egyir B, Guardabassi L, Nielsen SS, Larsen J, Addo KK, Newman MJ, et al. (2013). Prevalence of nasal carriage and diversity of Staphylococcus aureus among inpatients and hospital staff at Korle Bu Teaching Hospital, Ghana. J Glob. Antimicrob. Resist., 1, 189–193. https://doi.org/10.1016/j.jgar.2013.05.006 PMID: 27873611
40. Egyir B, Guardabassi L, Esson J, Nielsen SS, Newman MJ, Addo KK, et al. (2014). Insights into nasal carriage of Staphylococcus aureus in an urban and a rural community in Ghana. PLoS ONE, 9(4), 1–7. http://doi.org/10.1371/journal.pone.0096119.

41. Egyir B, Oteng AA, Owusu E, Newman MJ, Addo KK, & Rhod-Larsen A (2016). Characterization of Staphylococcus aureus from Human Immunodeficiency Virus (HIV) patients in Accra, Ghana. The Journal of Infection in Developing Countries, 10 (5), 453–456. http://doi.org/10.3855/jidc.7428 PMID: 27249519

42. Sampane-Donkor E, Badoe EV, Annan JA, & Nii-Trebi NI (2017). Colonization of antibiotic-resistant bacteria in a cohort of HIV infected children in Ghana. Pan African Medical Journal, 26, 1–7. http://doi.org/10.11604/pamj.2017.26.10.10981.

43. Donkor ES, Kotey FCN, Dayie NTKD, Duodu S, Tetteh-Quaeroo PB, Osei M-M, et al. (2019). Colonisation of HIV-infected children with methicillin-resistant Staphylococcus aureus. Pathogens, 8, 35. https://doi.org/10.3390/pathogens8050035 PMID: 30884909

44. Appiah VA, Pesewu GA, Kotey FCN, Boakye AN, & Nii-Trebi NI (2017). Colonisation of antibiotic-resistant bacteria in a cohort of HIV infected children in Ghana. Pan African Medical Journal, 26, 1–7. http://doi.org/10.11604/pamj.2017.26.10.10981.

45. Donkor ES, Jamrozy D, Mills RO, Dankwah T, Amoo PK, Egyir B, et al. (2018). A genomic infection control study for Staphylococcus aureus in two Ghanaian hospitals. Infect Drug Resist., 11, 1757–1765. https://doi.org/10.2147/IDR.S167639 PMID: 30345004

46. Omar N, Elnahas M, Elsotoby H, Eltarshoby M, & Stel O (2007). Methicillin-resistant Staphylococcus aureus monitoring in diabetic foot clinics (DFC). Journal of Medical Microbiology, 16(1), 29–37.

47. Lin J, Xu P, Peng Y, Lin D, Ou Q, Zhang T, et al. (2017). Prevalence and characteristics of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus nasal colonization among a community-based diabetes population. Journal of Diabetes Investigation, 8, 383–391. https://doi.org/10.1111/jdi.12591 PMID: 27809480

48. Lin S, Lin N, & Huang Y (2018). Methicillin-resistant Staphylococcus aureus nasal carriage and infection among patients with diabetic foot ulcer. Journal of Microbiology, Immunology and Infection, 20, 1–8. https://doi.org/10.1016/j.jmii.2018.03.005 PMID: 29907536

49. Kutlu SS, Cevahir N, Akalin S, et al. (2012). Prevalence and risk factors for methicillin-resistant Staphylococcus aureus colonization in a diabetic outpatient population: A prospective cohort study. Am J Infect Control, 40, 365–368. https://doi.org/10.1016/j.jic.2011.05.005 PMID: 21864943

50. Ahiuluwalla A, Sood A, Sood A, et al. (2000). Nasal colonization with Staphylococcus aureus in patients with diabetes mellitus. Diabet Med, 17, 487–488. https://doi.org/10.1046/j.1464-5491.2000.00297.x PMID: 10975221

51. Saxena AK, Panhotra BR, Venkateshappa CK, et al. (2002). The impact of nasal carriage of methicillin-resistant and methicillin-susceptible Staphylococcus aureus (MRSA & MSSA) on vascular access-related septicemia among patients with type-II diabetes on dialysis. Ren Fail, 24, 763–777. https://doi.org/10.1081/di-120015679 PMID: 12472199

52. Iwase T, Uehara Y, Shinji H, Tajima A, Seo H, Takada K, et al. (2010). Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization. Nature, 465 (7296), 346–349. http://doi.org/10.1038/nature09074 PMID: 20485435

53. Olson ME, Todd DA, Schaeffer CR, Paharik AE, Van Dyke MJ, Büttner H, et al. (2014). Staphylococcus epidermidis agr quorum-sensing system: signal identification, cross talk, and importance in colonization. Journal of Bacteriology, 196 (19), 3492–3493. http://doi.org/10.1128/jb.01882-14 PMID: 25070736

54. Paharik AE, Parlet CP, Chung N, Van Dyke MJ, Cech NB, & Horswill AR (2017). Coagulase-negative staphylococcal strain prevents Staphylococcus aureus colonization and skin infection by blocking quorum sensing. Cell Host and Microbe, 22 (6), 746–756. http://doi.org/10.1016/j.chom.2017.11.001s PMID: 29199097